| Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
|---|
| Ticlopidine | hsa00071 | Fatty acid degradation | 4.66E-02 | 3 | O75521, P11766, P33121 | ECI2, ADH5, ACSL1 | More | | | Ticlopidine | hsa00190 | Oxidative phosphorylation | 4.38E-04 | 3 | Q16718, Q13488, O14521 | NDUFA5, TCIRG1, SDHD | More | | | Ticlopidine | hsa00230 | Purine metabolism | 1.81E-02 | 2 | P20839, Q02153 | IMPDH1, GUCY1B3 | More | | | Ticlopidine | hsa00260 | Glycine, serine and threonine metabolism | 1.99E-02 | 1 | P22557 | ALAS2 | More | | | Ticlopidine | hsa00500 | Starch and sucrose metabolism | 9.22E-04 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | | | Ticlopidine | hsa00512 | Mucin type O-glycan biosynthesis | 3.78E-02 | 2 | O95395, Q8N4A0 | GCNT3, GALNT4 | More | | | Ticlopidine | hsa00565 | Ether lipid metabolism | 3.94E-02 | 1 | Q8N661 | TMEM86B | More | | | Ticlopidine | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | | | Ticlopidine | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | | | Ticlopidine | hsa00730 | Thiamine metabolism | 4.66E-02 | 2 | P05186, P24666 | ALPL, ACP1 | More | | | Ticlopidine | hsa00770 | Pantothenate and CoA biosynthesis | 2.26E-04 | 3 | O95498, O95497, Q9NRN7 | VNN2, VNN1, AASDHPPT | More | | | Ticlopidine | hsa00970 | Aminoacyl-tRNA biosynthesis | 9.22E-06 | 4 | O95363, P54136, P14868, Q15046 | FARS2, RARS1, DARS, KARS | More | | | Ticlopidine | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.14E-03 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | | Ticlopidine | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | | | Ticlopidine | hsa01523 | Antifolate resistance | 1.68E-02 | 2 | Q92820, P04818 | GGH, TYMS | More | | | Ticlopidine | hsa01524 | Platinum drug resistance | 1.79E-02 | 2 | O15392, P11388 | BIRC5, TOP2A | More | | | Ticlopidine | hsa02010 | ABC transporters | 2.29E-02 | 2 | P45844, P08183 | ABCG1, ABCB1 | More | | | Ticlopidine | hsa03018 | RNA degradation | 5.00E-02 | 1 | Q9NQT4 | EXOSC5 | More | | | Ticlopidine | hsa03022 | Basal transcription factors | 3.32E-02 | 2 | O00268, Q15544 | TAF4, TAF11 | More | | | Ticlopidine | hsa03040 | Spliceosome | 1.28E-05 | 13 | O43143, O60508, P08579, P26368, Q13595, Q07955, Q01130, P84103, Q13243, P11142, Q9Y2W2, O43447, O75643 | DHX15, CDC40, SNRPB2, U2AF2, TRA2A, SFRS1, SFRS2, SFRS3, SFRS5, HSPA8, WBP11, PPIH, ASCC3L1 | More | | | Ticlopidine | hsa03050 | Proteasome | 1.21E-02 | 1 | P28074 | PSMB5 | More | | | Ticlopidine | hsa04010 | MAPK signaling pathway | 1.53E-02 | 2 | Q9H2K8, Q12933 | TAOK3, TRAF2 | More | | | Ticlopidine | hsa04014 | Ras signaling pathway | 2.36E-02 | 8 | P42338, P20827, P49767, Q13009, Q7LDG7, P63218, P50151, P19174 | PIK3CB, EFNA1, VEGFC, TIAM1, RASGRP2, GNG5, GNG10, PLCG1 | More | | | Ticlopidine | hsa04015 | Rap1 signaling pathway | 1.79E-02 | 8 | P20827, P49767, Q96FS4, P11215, Q13009, Q7LDG7, P42338, P19174 | EFNA1, VEGFC, SIPA1, ITGAM, TIAM1, RASGRP2, PIK3CB, PLCG1 | More | | | Ticlopidine | hsa04062 | Chemokine signaling pathway | 1.43E-04 | 17 | P25024, P25025, P47992, Q9UBD3, P09769, P07948, P42338, P19174, P63218, P50151, P43250, P49407, Q08881, Q7LDG7, Q13009, P49841, Q8WYR1 | CXCR1, CXCR2, XCL1, XCL2, FGR, LYN, PIK3CB, PLCG1, GNG5, GNG10, GRK6, ARRB1, ITK, RASGRP2, TIAM1, GSK3B, PIK3R5 | More | | | Ticlopidine | hsa04064 | NF-kappa B signaling pathway | 3.99E-02 | 6 | P10415, Q13489, P29965, Q9UDY8, Q8WV28, Q13315 | BCL2, BIRC3, CD40LG, MALT1, BLNK, ATM | More | | | Ticlopidine | hsa04070 | Phosphatidylinositol signaling system | 3.47E-02 | 4 | P0DP23, Q14643, P23743, P17252 | CALM1, ITPR1, DGKA, PRKCA | More | | | Ticlopidine | hsa04071 | Sphingolipid signaling pathway | 4.58E-03 | 6 | P17252, Q13362, Q9BX95, P10415, Q12933, Q02156 | PRKCA, PPP2R5C, SGPP1, BCL2, TRAF2, PRKCE | More | | | Ticlopidine | hsa04110 | Cell cycle | 6.63E-04 | 6 | P06493, O60566, P30304, P33981, P42773, P01106 | CDK1, BUB1B, CDC25A, TTK, CDKN2C, MYC | More | | | Ticlopidine | hsa04114 | Oocyte meiosis | 1.33E-02 | 4 | P51812, Q02750, P16298, Q17RY0 | RPS6KA3, MAP2K1, PPP3CB, CPEB4 | More | | | Ticlopidine | hsa04120 | Ubiquitin mediated proteolysis | 2.51E-03 | 6 | Q14145, Q13042, P62837, Q15751, O95071, P0CG47 | KEAP1, CDC16, UBE2D2, HERC1, UBR5, UBB | More | | | Ticlopidine | hsa04137 | Mitophagy - animal | 9.52E-03 | 2 | Q07817, P0CG47 | BCL2L1, UBB | More | | | Ticlopidine | hsa04145 | Phagosome | 2.11E-04 | 10 | Q15080, P14598, Q13509, P68371, Q13488, P05164, P78380, O60603, P35443, P13765 | NCF4, NCF1, TUBB3, TUBB2C, TCIRG1, MPO, OLR1, TLR2, THBS4, HLA-DOB | More | | | Ticlopidine | hsa04150 | mTOR signaling pathway | 3.60E-02 | 3 | Q02750, Q9NQL2, P51812 | MAP2K1, RRAGD, RPS6KA3 | More | | | Ticlopidine | hsa04151 | PI3K-Akt signaling pathway | 5.33E-03 | 20 | P42338, P43657, P25116, P20827, P49767, Q13362, P08238, Q8WYR1, P62873, P63218, P50151, P16144, O15335, Q13751, O60603, P14784, P01568, P10415, P17252, P30281 | PIK3CB, P2RY5, F2R, EFNA1, VEGFC, PPP2R5C, HSP90AB1, PIK3R5, GNB1, GNG5, GNG10, ITGB4, CHAD, LAMB3, TLR2, IL2RB, IFNA21, BCL2, PRKCA, CCND3 | More | | | Ticlopidine | hsa04217 | Necroptosis | 6.91E-04 | 11 | P01375, P01568, P48023, Q13489, P42224, Q14765, Q6FI13, Q99878, P10415, O43633, Q08752 | TNF, IFNA21, FASLG, BIRC3, STAT1, STAT4, H2AC18; H2AC19, H2AC14, BCL2, CHMP2A, PPID | More | | | Ticlopidine | hsa04261 | Adrenergic signaling in cardiomyocytes | 2.84E-02 | 5 | P09493, Q13362, P0DP23, P17252, P10415 | TPM1, PPP2R5C, CALM1, PRKCA, BCL2 | More | | | Ticlopidine | hsa04360 | Axon guidance | 4.04E-02 | 6 | P16333, P20827, O95631, P42338, P07332, P19174 | NCK1, EFNA1, NTN1, PIK3CB, FES, PLCG1 | More | | | Ticlopidine | hsa04370 | VEGF signaling pathway | 2.68E-03 | 3 | P16298, Q05397, Q02750 | PPP3CB, PTK2, MAP2K1 | More | | | Ticlopidine | hsa04371 | Apelin signaling pathway | 1.00E-02 | 7 | P63218, P50151, Q8WYR1, Q14814, Q14344, Q13485, P84022 | GNG5, GNG10, PIK3R5, MEF2D, GNA13, SMAD4, SMAD3 | More | | | Ticlopidine | hsa04530 | Tight junction | 3.29E-02 | 3 | P16989, P56750, Q14247 | CSDA, CLDN17, CTTN | More | | | Ticlopidine | hsa04540 | Gap junction | 1.29E-02 | 4 | P17252, Q13509, P68371, Q14643 | PRKCA, TUBB3, TUBB2C, ITPR1 | More | | | Ticlopidine | hsa04612 | Antigen processing and presentation | 7.96E-06 | 9 | P13765, P48382, P26715, P26717, Q07444, Q13241, O43908, P01732, P01375 | HLA-DOB, RFX5, KLRC1, KLRC2, KLRC3, KLRD1, KLRC4, CD8A, TNF | More | | | Ticlopidine | hsa04613 | Neutrophil extracellular trap formation | 4.58E-05 | 21 | P17252, O60603, P05164, P08246, Q9UM07, Q13547, Q92769, P04908, Q6FI13, Q93077, P62807, O60814, P68431, P14598, Q15080, P08311, O75015, P21730, P21462, O43315, Q16539 | PRKCA, TLR2, MPO, ELA2, PADI4, HDAC1, HDAC2, H2AC4; H2AC8, H2AC18; H2AC19, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, NCF1, NCF4, CTSG, FCGR3B, C5AR1, FPR1, AQP9, MAPK14 | More | | | Ticlopidine | hsa04622 | RIG-I-like receptor signaling pathway | 2.47E-02 | 1 | Q12933 | TRAF2 | More | | | Ticlopidine | hsa04625 | C-type lectin receptor signaling pathway | 4.80E-02 | 6 | Q9ULY5, P20749, Q14643, P01375, Q13191, Q16539 | CLEC4E, BCL3, ITPR1, TNF, CBLB, MAPK14 | More | | | Ticlopidine | hsa04640 | Hematopoietic cell lineage | 1.37E-04 | 15 | P13612, P14778, P27930, P15144, P11836, P25063, P07766, P09693, P01732, P01730, P06127, P09564, P13765, P01375, P09603 | ITGA4, IL1R1, IL1R2, ANPEP, MS4A1, CD24, CD3E, CD3G, CD8A, CD4, CD5, CD7, HLA-DOB, TNF, CSF1 | More | | | Ticlopidine | hsa04650 | Natural killer cell mediated cytotoxicity | 9.55E-11 | 15 | P16298, P50591, P01375, P78314, P06239, O60880, P20963, Q02750, Q13241, P26718, O14931, O75015, P26717, Q07444, P26715 | PPP3CB, TNFSF10, TNF, SH3BP2, LCK, SH2D1A, CD247, MAP2K1, KLRD1, KLRK1, NCR3, FCGR3B, KLRC2, KLRC3, KLRC1 | More | | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
|---|
| P11511 | CYP19A1 | Aromatase | P16298 | PPP3CB | Serine/threonine-protein phosphatase 2B catalytic subunit beta isoform | 0.706 | | P11511 | CYP19A1 | Aromatase | P50591 | TNFSF10 | Tumor necrosis factor ligand superfamily member 10 | 0.701 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P01375 | TNF | Tumor necrosis factor | 0.718 | | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P01375 | TNF | Tumor necrosis factor | 0.774 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P78314 | SH3BP2 | SH3 domain-binding protein 2 | 0.748 | | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P78314 | SH3BP2 | SH3 domain-binding protein 2 | 0.809 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P06239 | LCK | Tyrosine-protein kinase Lck | -0.779 | | O14626 | GPR171 | Probable G-protein coupled receptor 171 | P06239 | LCK | Tyrosine-protein kinase Lck | 0.864 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | O60880 | SH2D1A | SH2 domain-containing protein 1A | -0.751 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | O60880 | SH2D1A | SH2 domain-containing protein 1A | -0.788 | | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | O60880 | SH2D1A | SH2 domain-containing protein 1A | -0.81 | | O14626 | GPR171 | Probable G-protein coupled receptor 171 | O60880 | SH2D1A | SH2 domain-containing protein 1A | 0.92 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.722 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.771 | | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.77 | | O14626 | GPR171 | Probable G-protein coupled receptor 171 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.898 | | P11511 | CYP19A1 | Aromatase | Q02750 | MAP2K1 | Dual specificity mitogen-activated protein kinase kinase 1 | 0.783 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.715 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.701 | | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.856 | | O14626 | GPR171 | Probable G-protein coupled receptor 171 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.809 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | -0.842 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | -0.81 | | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | -0.879 | | O14626 | GPR171 | Probable G-protein coupled receptor 171 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.818 | | O14626 | GPR171 | Probable G-protein coupled receptor 171 | O14931 | NCR3 | Natural cytotoxicity triggering receptor 3 | 0.765 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.913 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.896 | | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.893 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.714 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.721 | | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.838 | | O14626 | GPR171 | Probable G-protein coupled receptor 171 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.826 | | O14626 | GPR171 | Probable G-protein coupled receptor 171 | Q07444 | KLRC3 | NKG2-E type II integral membrane protein | 0.761 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.714 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.721 | | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.838 | | O14626 | GPR171 | Probable G-protein coupled receptor 171 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.826 |
| | Ticlopidine | hsa04657 | IL-17 signaling pathway | 2.81E-02 | 7 | O00463, Q16539, P49841, P09341, P14780, P80188, P01375 | TRAF5, MAPK14, GSK3B, CXCL1, MMP9, LCN2, TNF | More | | | Ticlopidine | hsa04658 | Th1 and Th2 cell differentiation | 1.08E-06 | 11 | Q04759, P07766, P20963, P09693, Q16539, P06239, Q14765, P23771, Q9UL17, P13765, Q13761 | PRKCQ, CD3E, CD247, CD3G, MAPK14, LCK, STAT4, GATA3, TBX21, HLA-DOB, RUNX3 | More | | | Ticlopidine | hsa04659 | Th17 cell differentiation | 8.40E-06 | 16 | Q04759, Q16539, P19174, P06239, P14784, P13765, P14778, Q9HBE5, Q9UL17, P23771, P84022, Q13485, P08238, P07766, P09693, P20963 | PRKCQ, MAPK14, PLCG1, LCK, IL2RB, HLA-DOB, IL1R1, IL21R, TBX21, GATA3, SMAD3, SMAD4, HSP90AB1, CD3E, CD3G, CD247 | More | | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
|---|
| P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q04759 | PRKCQ | Protein kinase C theta type | -0.762 | | O14626 | GPR171 | Probable G-protein coupled receptor 171 | Q04759 | PRKCQ | Protein kinase C theta type | 0.83 | | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.833 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | -0.766 | | O14626 | GPR171 | Probable G-protein coupled receptor 171 | P06239 | LCK | Tyrosine-protein kinase Lck | 0.864 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P14784 | IL2RB | Interleukin-2 receptor subunit beta | -0.835 | | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | -0.73 | | O14626 | GPR171 | Probable G-protein coupled receptor 171 | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.739 | | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.762 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.764 | | O14626 | GPR171 | Probable G-protein coupled receptor 171 | Q9HBE5 | IL21R | Interleukin-21 receptor | 0.764 | | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q9UL17 | TBX21 | T-box transcription factor TBX21 | -0.861 | | O14626 | GPR171 | Probable G-protein coupled receptor 171 | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.873 | | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | -0.767 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P84022 | SMAD3 | Mothers against decapentaplegic homolog 3 | 0.725 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13485 | SMAD4 | Mothers against decapentaplegic homolog 4 | -0.746 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | -0.823 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | -0.838 | | O14626 | GPR171 | Probable G-protein coupled receptor 171 | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.763 | | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.815 | | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.77 | | O14626 | GPR171 | Probable G-protein coupled receptor 171 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.898 |
| | Ticlopidine | hsa04660 | T cell receptor signaling pathway | 3.95E-07 | 12 | P01375, Q04759, O95267, Q08881, P07766, P20963, P09693, P01732, Q13191, P06239, Q16539, P49841 | TNF, PRKCQ, RASGRP1, ITK, CD3E, CD247, CD3G, CD8A, CBLB, LCK, MAPK14, GSK3B | More | | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
|---|
| P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P01375 | TNF | Tumor necrosis factor | 0.718 | | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P01375 | TNF | Tumor necrosis factor | 0.774 | | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q04759 | PRKCQ | Protein kinase C theta type | -0.762 | | O14626 | GPR171 | Probable G-protein coupled receptor 171 | Q04759 | PRKCQ | Protein kinase C theta type | 0.83 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | O95267 | RASGRP1 | RAS guanyl-releasing protein 1 | -0.716 | | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | O95267 | RASGRP1 | RAS guanyl-releasing protein 1 | -0.806 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | -0.746 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | -0.736 | | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | -0.812 | | O14626 | GPR171 | Probable G-protein coupled receptor 171 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | 0.761 | | O14626 | GPR171 | Probable G-protein coupled receptor 171 | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.763 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.722 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.771 | | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.77 | | O14626 | GPR171 | Probable G-protein coupled receptor 171 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.898 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.77 | | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.815 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | -0.722 | | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | -0.816 | | O14626 | GPR171 | Probable G-protein coupled receptor 171 | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | 0.841 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | -0.719 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | -0.734 | | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | -0.816 | | O14626 | GPR171 | Probable G-protein coupled receptor 171 | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | 0.714 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P06239 | LCK | Tyrosine-protein kinase Lck | -0.779 | | O14626 | GPR171 | Probable G-protein coupled receptor 171 | P06239 | LCK | Tyrosine-protein kinase Lck | 0.864 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.889 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.795 | | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.833 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.861 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.823 | | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.781 |
| | Ticlopidine | hsa04662 | B cell receptor signaling pathway | 1.74E-02 | 5 | P42338, P60033, P07948, P21854, Q8N149 | PIK3CB, CD81, LYN, CD72, LILRA2 | More | | | Ticlopidine | hsa04664 | Fc epsilon RI signaling pathway | 2.47E-02 | 4 | P42338, P07948, P19174, P09917 | PIK3CB, LYN, PLCG1, ALOX5 | More | | | Ticlopidine | hsa04672 | Intestinal immune network for IgA production | 3.76E-03 | 3 | P29965, P10747, P13765 | CD40LG, CD28, HLA-DOB | More | | | Ticlopidine | hsa04713 | Circadian entrainment | 2.60E-02 | 4 | P0DP23, P17252, P62873, Q14643 | CALM1, PRKCA, GNB1, ITPR1 | More | | | Ticlopidine | hsa04714 | Thermogenesis | 5.21E-03 | 4 | Q16539, P33121, Q16718, O14521 | MAPK14, ACSL1, NDUFA5, SDHD | More | | | Ticlopidine | hsa04720 | Long-term potentiation | 1.95E-03 | 6 | P17252, P16298, P0DP23, P51812, Q02750, Q14643 | PRKCA, PPP3CB, CALM1, RPS6KA3, MAP2K1, ITPR1 | More | | | Ticlopidine | hsa04722 | Neurotrophin signaling pathway | 3.27E-02 | 3 | P49841, O43524, P48023 | GSK3B, FOXO3, FASLG | More | | | Ticlopidine | hsa04723 | Retrograde endocannabinoid signaling | 1.88E-02 | 4 | Q14643, P17252, P62873, Q16718 | ITPR1, PRKCA, GNB1, NDUFA5 | More | | | Ticlopidine | hsa04725 | Cholinergic synapse | 1.88E-02 | 4 | Q14643, P17252, P62873, P10415 | ITPR1, PRKCA, GNB1, BCL2 | More | | | Ticlopidine | hsa04728 | Dopaminergic synapse | 2.76E-03 | 11 | Q14643, P17252, P14416, P62873, P63218, P50151, P49841, Q16539, P49407, Q13362, P0DP23 | ITPR1, PRKCA, DRD2, GNB1, GNG5, GNG10, GSK3B, MAPK14, ARRB1, PPP2R5C, CALM1 | More | | | Ticlopidine | hsa04744 | Phototransduction | 1.02E-02 | 2 | P62873, P0DP23 | GNB1, CALM1 | More | | | Ticlopidine | hsa04750 | Inflammatory mediator regulation of TRP channels | 4.74E-02 | 3 | P22694, P24723, Q04759 | PRKACB, PRKCH, PRKCQ | More | | | Ticlopidine | hsa04912 | GnRH signaling pathway | 4.59E-03 | 6 | P17252, Q16539, Q9Y6R4, Q14643, P0DP23, P22694 | PRKCA, MAPK14, MAP3K4, ITPR1, CALM1, PRKACB | More | | | Ticlopidine | hsa04913 | Ovarian steroidogenesis | 2.72E-02 | 2 | P42330, P22694 | AKR1C3, PRKACB | More | | | Ticlopidine | hsa04914 | Progesterone-mediated oocyte maturation | 2.94E-02 | 3 | Q17RY0, P51812, Q02750 | CPEB4, RPS6KA3, MAP2K1 | More | | | Ticlopidine | hsa04920 | Adipocytokine signaling pathway | 4.72E-02 | 4 | P33121, Q04759, Q9Y4H2, P01375 | ACSL1, PRKCQ, IRS2, TNF | More | | | Ticlopidine | hsa04922 | Glucagon signaling pathway | 3.47E-02 | 4 | Q12778, Q13370, P0DP23, Q14643 | FOXO1, PDE3B, CALM1, ITPR1 | More | | | Ticlopidine | hsa04924 | Renin secretion | 8.71E-03 | 3 | Q14643, Q13370, P0DP23 | ITPR1, PDE3B, CALM1 | More | | | Ticlopidine | hsa04930 | Type II diabetes mellitus | 2.47E-02 | 1 | Q02156 | PRKCE | More | | | Ticlopidine | hsa04932 | Non-alcoholic fatty liver disease | 2.44E-03 | 5 | P01375, P49841, P48023, Q16718, O14521 | TNF, GSK3B, FASLG, NDUFA5, SDHD | More | | | Ticlopidine | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 1.19E-03 | 9 | P84022, Q13485, P42224, P10415, P42338, Q12778, P49767, P17252, P19174 | SMAD3, SMAD4, STAT1, BCL2, PIK3CB, FOXO1, VEGFC, PRKCA, PLCG1 | More | | | Ticlopidine | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | | Ticlopidine | hsa04966 | Collecting duct acid secretion | 2.86E-02 | 2 | Q13488, Q9Y666 | TCIRG1, SLC12A7 | More | | | Ticlopidine | hsa04974 | Protein digestion and absorption | 2.47E-02 | 1 | Q7Z2H8 | SLC36A1 | More | | | Ticlopidine | hsa04976 | Bile secretion | 3.32E-02 | 2 | O43315, P08183 | AQP9, ABCB1 | More | | | Ticlopidine | hsa05010 | Alzheimer disease | 3.55E-02 | 7 | Q16718, O14521, Q14643, P0DP23, Q13509, P68371, Q08752 | NDUFA5, SDHD, ITPR1, CALM1, TUBB3, TUBB2C, PPID | More | | | Ticlopidine | hsa05012 | Parkinson disease | 2.25E-02 | 6 | Q16718, O14521, Q14643, P0DP23, Q13509, P68371 | NDUFA5, SDHD, ITPR1, CALM1, TUBB3, TUBB2C | More | | | Ticlopidine | hsa05017 | Spinocerebellar ataxia | 2.43E-02 | 1 | P28074 | PSMB5 | More | | | Ticlopidine | hsa05020 | Prion disease | 1.31E-03 | 9 | Q16718, O14521, Q14643, Q13509, P68371, P49841, P14598, Q15080, Q16539 | NDUFA5, SDHD, ITPR1, TUBB3, TUBB2C, GSK3B, NCF1, NCF4, MAPK14 | More | | | Ticlopidine | hsa05022 | Pathways of neurodegeneration - multiple diseases | 2.00E-04 | 12 | Q14643, Q13509, P68371, P49841, P10415, Q16718, O14521, Q13561, P17252, Q16539, Q08752, P0DP23 | ITPR1, TUBB3, TUBB2C, GSK3B, BCL2, NDUFA5, SDHD, DCTN2, PRKCA, MAPK14, PPID, CALM1 | More | | | Ticlopidine | hsa05034 | Alcoholism | 2.89E-03 | 4 | Q93077, P62807, O60814, P68431 | HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | | Ticlopidine | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 3.11E-02 | 4 | Q16539, P25024, P25025, P07948 | MAPK14, CXCR1, CXCR2, LYN | More | | | Ticlopidine | hsa05131 | Shigellosis | 3.33E-03 | 10 | Q12933, P68431, Q02156, Q9UDY8, Q14247, Q14643, Q12778, Q13315, P10415, Q08752 | TRAF2, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, PRKCE, MALT1, CTTN, ITPR1, FOXO1, ATM, BCL2, PPID | More | | | Ticlopidine | hsa05132 | Salmonella infection | 1.11E-02 | 8 | Q9UJU2, Q13489, P10415, O60603, Q9BQS8, Q13561, Q13509, P68371 | LEF1, BIRC3, BCL2, TLR2, FYCO1, DCTN2, TUBB3, TUBB2C | More | | | Ticlopidine | hsa05135 | Yersinia infection | 4.65E-02 | 5 | P13612, P06239, Q16539, P01375, P49841 | ITGA4, LCK, MAPK14, TNF, GSK3B | More | | | Ticlopidine | hsa05140 | Leishmaniasis | 1.18E-04 | 10 | P13612, O75015, P14598, P42224, P13765, O60603, P01375, P29350, Q16539, Q15080 | ITGA4, FCGR3B, NCF1, STAT1, HLA-DOB, TLR2, TNF, PTPN6, MAPK14, NCF4 | More | | | Ticlopidine | hsa05143 | African trypanosomiasis | 2.72E-02 | 2 | P01375, P48023 | TNF, FASLG | More | | | Ticlopidine | hsa05144 | Malaria | 7.10E-05 | 5 | P60033, O60603, P01375, P35443, P26718 | CD81, TLR2, TNF, THBS4, KLRK1 | More | | | Ticlopidine | hsa05145 | Toxoplasmosis | 1.11E-02 | 6 | P10415, Q13489, P42224, P13765, O60603, P29965 | BCL2, BIRC3, STAT1, HLA-DOB, TLR2, CD40LG | More | | | Ticlopidine | hsa05146 | Amoebiasis | 3.54E-05 | 10 | P09341, P19875, P14778, P27930, P01375, O60603, P05089, P22694, P12814, P08311 | CXCL1, CXCL2, IL1R1, IL1R2, TNF, TLR2, ARG1, PRKACB, ACTN1, CTSG | More | | | Ticlopidine | hsa05152 | Tuberculosis | 7.93E-04 | 8 | Q13488, P0DP23, P42224, O60603, P10415, P13765, P01568, Q9UDY8 | TCIRG1, CALM1, STAT1, TLR2, BCL2, HLA-DOB, IFNA21, MALT1 | More | | | Ticlopidine | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | | | Ticlopidine | hsa05163 | Human cytomegalovirus infection | 1.72E-02 | 8 | P01375, P63218, P50151, P49841, P14778, P25025, Q16539, O00463 | TNF, GNG5, GNG10, GSK3B, IL1R1, CXCR2, MAPK14, TRAF5 | More | | | Ticlopidine | hsa05165 | Human papillomavirus infection | 3.10E-02 | 8 | P16144, Q05086, P01568, P42224, Q13488, Q13362, Q12778, Q13315 | ITGB4, UBE3A, IFNA21, STAT1, TCIRG1, PPP2R5C, FOXO1, ATM | More | | | Ticlopidine | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 3.04E-03 | 10 | P01568, P42224, P62873, P62879, P16298, Q14643, Q02750, P0DP23, P0CG47, Q9UJU2 | IFNA21, STAT1, GNB1, GNB2, PPP3CB, ITPR1, MAP2K1, CALM1, UBB, LEF1 | More | | | Ticlopidine | hsa05170 | Human immunodeficiency virus 1 infection | 8.44E-05 | 14 | Q02750, P62873, P62879, P16298, P0DP23, Q05397, P17252, Q14643, P01568, O60603, Q13315, P10415, Q9Y6Q5, P20333 | MAP2K1, GNB1, GNB2, PPP3CB, CALM1, PTK2, PRKCA, ITPR1, IFNA21, TLR2, ATM, BCL2, AP1M2, TNFRSF1B | More | | | Ticlopidine | hsa05200 | Pathways in cancer | 1.55E-03 | 28 | Q13751, P42338, P08238, P42224, P19174, Q9UJU2, P17252, P43246, P84022, Q13485, Q13547, P14923, P30281, P10415, Q13489, P49767, Q12778, P43657, P25116, P62873, P63218, P50151, Q14344, Q7LDG7, O75293, P0DP23, P01568, P14784 | LAMB3, PIK3CB, HSP90AB1, STAT1, PLCG1, LEF1, PRKCA, MSH2, SMAD3, SMAD4, HDAC1, JUP, CCND3, BCL2, BIRC3, VEGFC, FOXO1, P2RY5, F2R, GNB1, GNG5, GNG10, GNA13, RASGRP2, GADD45B, CALM1, IFNA21, IL2RB | More | | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
|---|
| P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13751 | LAMB3 | Laminin subunit beta-3 | 0.844 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | 0.777 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | -0.823 | | P17252 | PRKCA | Protein kinase C alpha type | P42224 | STAT1 | Signal transducer and activator of transcription 1-alpha/beta | -0.706 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | -0.766 | | P17252 | PRKCA | Protein kinase C alpha type | Q9UJU2 | LEF1 | Lymphoid enhancer-binding factor 1 | 0.881 | | P17252 | PRKCA | Protein kinase C alpha type | P17252 | PRKCA | Protein kinase C alpha type | 1 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P43246 | MSH2 | DNA mismatch repair protein Msh2 | -0.811 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P84022 | SMAD3 | Mothers against decapentaplegic homolog 3 | 0.725 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13485 | SMAD4 | Mothers against decapentaplegic homolog 4 | -0.746 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13547 | HDAC1 | Histone deacetylase 1 | -0.754 | | P17252 | PRKCA | Protein kinase C alpha type | P14923 | JUP | Junction plakoglobin | 0.761 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P30281 | CCND3 | G1/S-specific cyclin-D3 | 0.743 | | P17252 | PRKCA | Protein kinase C alpha type | P10415 | BCL2 | Apoptosis regulator Bcl-2 | 0.844 | | P17252 | PRKCA | Protein kinase C alpha type | Q13489 | BIRC3 | Baculoviral IAP repeat-containing protein 3 | 0.849 | | P17252 | PRKCA | Protein kinase C alpha type | P49767 | VEGFC | Vascular endothelial growth factor C | 0.719 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P49767 | VEGFC | Vascular endothelial growth factor C | 0.743 | | P17252 | PRKCA | Protein kinase C alpha type | Q12778 | FOXO1 | Forkhead box protein O1 | 0.863 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P43657 | P2RY5 | Lysophosphatidic acid receptor 6 | -0.735 | | P17252 | PRKCA | Protein kinase C alpha type | P25116 | F2R | Proteinase-activated receptor 1 | 0.857 | | P17252 | PRKCA | Protein kinase C alpha type | P62873 | GNB1 | Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 | -0.852 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P63218 | GNG5 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5 | 0.941 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | 0.948 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q14344 | GNA13 | Guanine nucleotide-binding protein subunit alpha-13 | 0.87 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q7LDG7 | RASGRP2 | RAS guanyl-releasing protein 2 | 0.704 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | O75293 | GADD45B | Growth arrest and DNA damage-inducible protein GADD45 beta | 0.731 | | P17252 | PRKCA | Protein kinase C alpha type | P0DP23 | CALM1 | Calmodulin-1 | -0.776 | | P17252 | PRKCA | Protein kinase C alpha type | P01568 | IFNA21 | Interferon alpha-21 | 0.733 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P14784 | IL2RB | Interleukin-2 receptor subunit beta | -0.835 |
| | Ticlopidine | hsa05202 | Transcriptional misregulation in cancer | 2.41E-03 | 15 | P41732, P14780, P27930, Q16548, Q13077, P35226, P05164, P12838, P08246, Q9C0K0, P41182, Q13547, Q92769, P12980, P24522 | TSPAN7, MMP9, IL1R2, BCL2A1, TRAF1, BMI1, MPO, DEFA4, ELA2, BCL11B, BCL6, HDAC1, HDAC2, LYL1, GADD45A | More | | | Ticlopidine | hsa05203 | Viral carcinogenesis | 4.85E-02 | 3 | Q15283, P62807, O60814 | RASA2, HIST1H2BC, H2BC12 | More | | | Ticlopidine | hsa05204 | Chemical carcinogenesis | 1.48E-02 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | | Ticlopidine | hsa05212 | Pancreatic cancer | 3.94E-02 | 4 | P42338, P84022, Q13485, O75293 | PIK3CB, SMAD3, SMAD4, GADD45B | More | | | Ticlopidine | hsa05213 | Endometrial cancer | 3.79E-02 | 2 | O15169, Q02750 | AXIN1, MAP2K1 | More | | | Ticlopidine | hsa05220 | Chronic myeloid leukemia | 2.16E-02 | 5 | Q13547, Q13485, P84022, P42338, O75293 | HDAC1, SMAD4, SMAD3, PIK3CB, GADD45B | More | | | Ticlopidine | hsa05226 | Gastric cancer | 3.79E-02 | 2 | Q02750, O15169 | MAP2K1, AXIN1 | More | | | Ticlopidine | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 2.73E-02 | 4 | P07766, P20963, P06239, Q04759 | CD3E, CD247, LCK, PRKCQ | More | | | Ticlopidine | hsa05310 | Asthma | 2.72E-02 | 2 | P13765, P12724 | HLA-DOB, RNASE3 | More | | | Ticlopidine | hsa05320 | Autoimmune thyroid disease | 1.27E-03 | 4 | P13765, P29965, P01568, P10747 | HLA-DOB, CD40LG, IFNA21, CD28 | More | | | Ticlopidine | hsa05321 | Inflammatory bowel disease | 2.02E-05 | 7 | O60603, P01375, P13765, Q14765, Q9UL17, P23771, Q9HBE5 | TLR2, TNF, HLA-DOB, STAT4, TBX21, GATA3, IL21R | More | | | Ticlopidine | hsa05322 | Systemic lupus erythematosus | 4.80E-06 | 10 | P08246, P09871, P10747, P13765, P29965, Q6FI13, Q93077, P62807, O60814, P68431 | ELA2, C1S, CD28, HLA-DOB, CD40LG, H2AC18; H2AC19, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | | Ticlopidine | hsa05323 | Rheumatoid arthritis | 1.31E-04 | 7 | P09603, P13765, Q13488, P10747, P09341, P19875, O60603 | CSF1, HLA-DOB, TCIRG1, CD28, CXCL1, CXCL2, TLR2 | More | | | Ticlopidine | hsa05330 | Allograft rejection | 1.04E-03 | 5 | P13765, P29965, P48023, P10747, P01375 | HLA-DOB, CD40LG, FASLG, CD28, TNF | More | | | Ticlopidine | hsa05332 | Graft-versus-host disease | 1.05E-04 | 5 | P13765, P48023, P01375, P26715, Q13241 | HLA-DOB, FASLG, TNF, KLRC1, KLRD1 | More | | | Ticlopidine | hsa05340 | Primary immunodeficiency | 2.86E-02 | 3 | P01732, P07766, P06239 | CD8A, CD3E, LCK | More | | | Ticlopidine | hsa05415 | Diabetic cardiomyopathy | 1.58E-03 | 7 | P17252, P14598, Q15080, Q16718, O14521, Q16539, P49841 | PRKCA, NCF1, NCF4, NDUFA5, SDHD, MAPK14, GSK3B | More | | | Ticlopidine | hsa05416 | Viral myocarditis | 2.62E-02 | 3 | P13765, P29965, P10747 | HLA-DOB, CD40LG, CD28 | More | | | Ticlopidine | hsa05418 | Fluid shear stress and atherosclerosis | 3.61E-02 | 6 | Q16539, P10599, P14780, P01375, P14778, P27930 | MAPK14, TXN, MMP9, TNF, IL1R1, IL1R2 | More | |
|
